Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm

Documenti analoghi

• Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms
  di: Halpern, Anna B., et al.
  Pubblicazione: (2019)
• Phase 1/2 Trial of GCLAM with Dose-Escalated Mitoxantrone for Newly Diagnosed AML or Other High-Grade Myeloid Neoplasms
  di: Halpern, Anna B., et al.
  Pubblicazione: (2018)
• Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility
  di: Percival, Mary-Elizabeth M., et al.
  Pubblicazione: (2020)
• Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms: A Phase 1/2 Study
  di: Halpern, Anna B., et al.
  Pubblicazione: (2017)
• Diagnostic Utility of Bronchoscopy in Adults with Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
  di: Buckley, Sarah A., et al.
  Pubblicazione: (2019)